MedTrace Logo

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

NCT00014651 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2010-08-10

No results posted yet for this study

Summary

RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection.

PURPOSE: This randomized phase III trial is studying vapreotide to see how well it works compared to a placebo in preventing complications in patients undergoing surgery for pancreatic cancer.

Conditions

Interventions

DRUG

vapreotide

PROCEDURE

conventional surgery

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Michael G. Sarr, MD, FACS · Mayo Clinic

Study Design

Purpose
SUPPORTIVE_CARE

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2001-03-31
Completion
2002-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00014651 on ClinicalTrials.gov